Stifel Nicolaus Forecasts Strong Price Appreciation for DRI Healthcare Trust (TSE:DHT.UN) Stock

DRI Healthcare Trust (TSE:DHT.UN) had its price target upped by research analysts at Stifel Nicolaus from C$23.00 to C$24.00 in a research report issued to clients and investors on Tuesday,BayStreet.CA reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 33.26% from the company’s previous close.

DHT.UN has been the subject of several other research reports. Raymond James Financial raised their price objective on shares of DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock a “strong-buy” rating in a research report on Monday. National Bank Financial lifted their price target on shares of DRI Healthcare Trust from C$22.50 to C$23.50 and gave the company an “outperform” rating in a research note on Tuesday, May 19th. Finally, Scotiabank upped their target price on DRI Healthcare Trust from C$25.00 to C$30.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company’s stock. According to MarketBeat.com, DRI Healthcare Trust has an average rating of “Buy” and a consensus target price of C$24.80.

DRI Healthcare Trust Trading Down 2.7%

TSE DHT.UN traded down C$0.50 during trading hours on Tuesday, hitting C$18.01. 45,612 shares of the company’s stock were exchanged, compared to its average volume of 59,601. The firm has a market cap of C$990.84 million, a price-to-earnings ratio of -20.01 and a beta of 0.47. The stock has a 50-day simple moving average of C$17.17 and a 200 day simple moving average of C$16.64. DRI Healthcare Trust has a 1-year low of C$13.24 and a 1-year high of C$19.04.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is managed by DRI Capital Inc DRI a pioneer in global pharmaceutical royalty monetization. We provide uniquely favorable exposure for investors in the biopharma industry managing a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world and aiming to acquire dependable patent-protected cash flow streams derived from the sales of those important drugs while limiting the risks and costs connected to drug development. DRI has developed a disciplined strategy predicated on actively sourcing royalty streams on medically necessary products and proudly work with multiple repeat deal partners.DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario pursuant to a declaration of trust dated October 21 2020 as amended.DRI Healthcare Trusts units are listed and trade on the Toronto Stock Exchange under DHT.UN in Canadian dollars and under DHT.U in U.S.